Asset
SERALUTINIB
GOSSAMER BIO INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03926793 | phase1 | completed | 2020-02-04 | 2021-05-05 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension |
| NCT05934526 | phase3 | completed | 2023-12-28 | 2025-11-27 | GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) |
| NCT07181382 | phase3 | suspended | 2026-02-01 | 2028-12-01 | GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
| NCT04456998 | phase2 | completed | 2020-11-12 | 2022-10-17 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) |
| NCT04816604 | phase2 | terminated | 2021-04-05 | 2026-09-09 | Gossamer Bio USA, Inc. | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) |
FDA applications (0)
This company has no applications containing this asset.